Compare Hut 8 Corp (HUT) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Johnson & Johnson — how do they compare? Hut 8 Corp trades at $84.2 (market cap $9.82B), while Johnson & Johnson trades at $261.07 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 62.9× Hut 8 Corp's market cap, and Johnson & Johnson pays a 2.09% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Johnson & Johnson for 129 Days on average.
| HUT | JNJ | |
|---|---|---|
Market Cap | $9.82B | $618.09B |
Volume | 10,272,678 | 6,050,983 |
Sector | Financials | Health |
52-Week High | $133.02 | $278.43 |
52-Week Low | $33.76 | $186.00 |
Typical Hold Time | 11 Days | 129 Days |
Enterprise Value | $17.25B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hut 8 Corp. (HUT) trades at $81.20, down 9.07% amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, with negative cash flow from operations. Recent news highlights a $1.07 billion credit facility and strong analyst buy ratings, with a consensus price target of $162.69 suggesting significant upside potential.
The outlook is mixed: robust analyst support and AI infrastructure growth opportunities contrast with persistent losses and high valuation ratios. Key risks include execution on profitability and sensitivity to sector sentiment. The stock's near-term direction hinges on earnings improvement and contract execution.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
